BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-sanofi-sarclisa-sc-pdufa-july-2026@catalyst-calendar.local
DTSTAMP:20260720T200622Z
DTSTART:20260723T130000Z
DTEND:20260723T133000Z
SUMMARY:Sanofi Sarclisa皮下注射剂型多发性骨髓瘤BLA PDUFA日期
DESCRIPTION:Sanofi披露FDA将Sarclisa皮下注射剂型sBLA审评目标日期延长至2026年7月23日。若获批，Sarclisa SC将成为美国首个通过on-body injector给药的抗癌治疗之一。\\nImpact score: 66\\nExpected: FDA决定将影响多发性骨髓瘤抗CD38给药便利性竞争和on-body injector在肿瘤药中的采用预期。\\nAffected: SNY(subject\, mixed\, score 72)\; JNJ(peer\, mixed\, score 56)\; BMY(peer\, mixed\, score 54)\; IBB(etf\, mixed\, score 44)\\nSources: Sanofi Sarclisa SC update: https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-00-00-3278646\\nSanofi US newsroom release: https://www.news.sanofi.us/2026-04-22-Sanofi-provides-update-on-the-regulatory-submission-for-Sarclisa-subcutaneous-in-the-US\\nSanofi EU approval release: https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-08-05-00-00-3307781\\nSanofi IRAKLIA phase 3: https://www.sanofi.com/en/media-room/press-releases/2025/2025-01-09-06-00-00-3006798\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-sanofi-sarclisa-sc-pdufa-july-2026
CATEGORIES:fda\,US\,FDA\,PDUFA\,multiple myeloma\,CD38\,on-body injector\,drug delivery
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Sanofi Sarclisa皮下注射剂型多发性骨髓瘤BLA PDUFA日期
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Sanofi Sarclisa皮下注射剂型多发性骨髓瘤BLA PDUFA日期
END:VALARM
END:VEVENT
END:VCALENDAR